Prenetics Global (PRE) Set to Release Quarterly Earnings on Monday

Posted by Stanley Muller on Nov 2nd, 2026

Prenetics Global (NASDAQ:PRE – Get Free Report) is expected to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.82) per share and revenue of $63.28 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Prenetics Global (NASDAQ:PRE – Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The business had revenue of $46.49 million for the quarter, compared to analysts’ expectations of $49.85 million. On average, analysts expect Prenetics Global to post ($1.86) EPS for the current fiscal year and ($1.15) EPS for the next fiscal year.

Prenetics Global Price Performance

Shares of NASDAQ:PRE opened at $17.76 on Monday. The firm’s 50 day simple moving average is $22.07 and its two-hundred day simple moving average is $19.58. Prenetics Global has a 1-year low of $11.36 and a 1-year high of $27.24. The company has a market capitalization of $299.61 million, a P/E ratio of -4.27 and a beta of 0.40.

Analyst Ratings Changes

Several brokerages have issued reports on PRE. Benchmark raised their price objective on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. B. Riley Financial assumed coverage on Prenetics Global in a research note on Thursday, August 27th. They issued a “buy” rating and a $37.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, October 15th. Craig Hallum initiated coverage on shares of Prenetics Global in a research note on Thursday, September 17th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Lucid Cap Mkts raised Prenetics Global to a “strong-buy” rating in a research report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Prenetics Global presently has an average rating of “Moderate Buy” and an average target price of $37.17.

Check Out Our Latest Analysis on Prenetics Global

Insider Transactions at Prenetics Global

In other news, CFO Brian Rosin purchased 5,100 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was purchased at an average cost of $22.80 per share, with a total value of $116,280.00. Following the completion of the acquisition, the chief financial officer directly owned 23,100 shares of the company’s stock, valued at approximately $526,680. This trade represents a 28.33% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Danny Sheng Wu Yeung purchased 17,181 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was purchased at an average price of $21.23 per share, for a total transaction of $364,752.63. Following the acquisition, the chief executive officer owned 112,416 shares in the company, valued at approximately $2,386,591.68. This trade represents a 18.04% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 47,781 shares of company stock valued at $999,778 over the last ninety days.

Prenetics Global Company Profile

(Get Free Report)

Prenetics Global Limited is a health sciences and genomics company founded in 2014 by Danny Yeung, who serves as its chief executive officer. Headquartered in Hong Kong, the company uses genetic sequencing, molecular diagnostics and data analysis to support consumer health, clinical care and early disease detection.

Its consumer business operates under the CircleDNA brand, which offers at-home DNA testing and reports covering areas such as wellness, nutrition, fitness, traits and genetic risk.